Related Experiment Video
Updated: Sep 15, 2025
High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
Published on: June 16, 2018
Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality
Xiang Li1,2,3,4,5,6,7,8, Si-Qi Zhang9, Ke-Rui Wang1,2
1Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Objective:
This study aimed to evaluate the risk of adverse events associated with chloroquine (CQ) and hydroxychloroquine (HCQ) in patients with systemic lupus erythematosus (SLE), using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Methods:
Disproportionality analysis was conducted using the Reporting Odds Ratio (ROR) to detect potential safety signals. Sensitivity analyses were performed to validate these signals, and the time to onset for each Preferred Term (PT) was assessed.
Results:
Between 2004 and 2024, a total of 2,575 adverse event reports related to HCQ or CQ use in patients with SLE were identified in the FAERS database, of which 437 involved ocular adverse events. The most frequently reported ocular conditions were cataract, macular degeneration, and glaucoma. Disproportionality analysis demonstrated strong associations between HCQ/CQ use and retinal degeneration (ROR = 28.5, 95%CI: 19.94-40.74), cystoid macular oedema (ROR = 12.46, 95%CI: 8.01-19.37), and optic atrophy (ROR = 6.55, 95%CI: 3.51-12.19). Sensitivity analyses, conducted after excluding SLE cases, indicated that all but one event (vitreous floaters) remained statistically significant, suggesting that these risks are more likely attributable to HCQ/CQ exposure than to the underlying disease. The time-to-onset analysis showed that cataract had the shortest average onset time (125.5 days), whereas retinal degeneration had the longest (937.5 days).
Conclusion:
The extensive clinical use of HCQ and CQ raises significant concerns regarding their ocular safety profile. This study provides real-world pharmacovigilance evidence supporting a substantial risk of ocular adverse events associated with HCQ/CQ use. Further mechanistic and prospective studies are warranted to elucidate the underlying pathophysiological pathways and to confirm these associations.
